Browsing by Author "Cejalvo, Juan M."

Sort by: Order: Results:

  • A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
    Cejalvo, Juan M.; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martínez-García, Maria; Taus García, Álvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine; Michielin, Francesca; James, Ian; Ceppi, Maurizio; Hasmann, Max; Weisser, Martin; Cervantes, Andrés (BMJ Publishing Group, 2019)
    PURPOSE:This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in ...
  • Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer
    Cejalvo, Juan M.; Albanell Mestres, Joan; Prat, Aleix (American Association for Cancer Research (AACR), 2017)
    Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and ...
  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • mTOR inhibition and T-DM1 in HER2-positive breast cancer
    Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2022)
    In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR ...
  • Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna; Rovira Guerín, Ana; Albanell Mestres, Joan; Arribas, Joaquín; Cejalvo, Juan M. (American Association for the Advancement of Science (AAAS), 2022)
    Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking